Empowering Venture Capital Associates
What does it take to turn breakthrough science into a breakthrough company? In this episode of the NextGen VC Podcast, we sit down with Noreen Rizvi, PhD, Principal at Third Rock Ventures, whose journey from chemical engineering to venture creation offers a rare look inside the art and science of biotech investing. Noreen discusses how she bridges science and strategy, what she’s learned from building companies like Trace Neuro and Faze Medicine, and why Third Rock spends years incubating ideas before launch. She also shares how mentorship, collaboration, and a “take the call” mindset have shaped her path. Tune in for a grounded, inside look at company creation, risk-taking, and the evolving biotech landscape from RNA therapeutics to the next generation of life science innovation.
Mike is a partner in the San Francisco (SoMa) and San Diego offices of Wilson Sonsini Goodrich & Rosati. He has provided strategic intellectual property counseling to hundreds growth enterprises in the pharmaceutical and biotechnology industries, both venture-backed and public companies. His expertise includes patent strategy, prosecution, and diligence (both buy and sell side) for venture financings, public offerings, mergers and acquisitions.
Jennifer is a partner in the Boston office of Wilson Sonsini Goodrich & Rosati. She helps innovative startups grow into successful enterprises by providing counsel to the founders, management teams and boards and by handling the legal and strategic business issues and transactions that arise at each stage. She is a member of the National Venture Capital Association (NVCA) General Counsel Advisory Board and is a frequent speaker.
Powered by LaunchBio with generous support from Wilson Sonsini
